Geode Capital Management’s Charles River Laboratories CRL Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$296M Buy
1,305,738
+44
+0% +$7.83K 0.02% 644
2026
Q1
$225M Buy
1,305,694
+29,192
+2% +$5.41M 0.01% 684
2025
Q4
$254M Buy
1,276,502
+9,756
+0.8% +$1.77M 0.02% 635
2025
Q3
$198M Buy
1,266,746
+34,516
+3% +$5.48M 0.01% 705
2025
Q2
$187M Sell
1,232,230
-31,435
-2% -$4.19M 0.01% 692
2025
Q1
$190M Buy
1,263,665
+30,454
+2% +$5.11M 0.01% 653
2024
Q4
$227M Buy
1,233,211
+14,787
+1% +$2.85M 0.02% 593
2024
Q3
$239M Buy
1,218,424
+1,631
+0.1% +$339K 0.02% 577
2024
Q2
$251M Buy
1,216,793
+30,949
+3% +$7.01M 0.02% 522
2024
Q1
$320M Buy
1,185,844
+39,835
+3% +$9.51M 0.03% 473
2023
Q4
$270M Buy
1,146,009
+23,186
+2% +$4.56M 0.03% 486
2023
Q3
$220M Buy
1,122,823
+21,423
+2% +$4.4M 0.03% 506
2023
Q2
$231M Buy
1,101,400
+38,984
+4% +$7.76M 0.03% 500
2023
Q1
$214M Buy
1,062,416
+25,019
+2% +$5.67M 0.03% 500
2022
Q4
$226M Buy
1,037,397
+42,486
+4% +$9.28M 0.03% 474
2022
Q3
$196M Buy
994,911
+26,168
+3% +$5.65M 0.03% 484
2022
Q2
$207M Buy
968,743
+10,119
+1% +$2.47M 0.03% 485
2022
Q1
$272M Buy
958,624
+33,886
+4% +$10.4M 0.03% 464
2021
Q4
$348M Buy
924,738
+13,586
+1% +$5.28M 0.04% 410
2021
Q3
$375M Buy
911,152
+35,148
+4% +$14.6M 0.05% 359
2021
Q2
$323M Buy
876,004
+286,056
+48% +$95.5M 0.04% 396
2021
Q1
$171M Buy
589,948
+26,620
+5% +$7.4M 0.03% 552
2020
Q4
$141M Buy
563,328
+31,759
+6% +$7.56M 0.02% 572
2020
Q3
$120M Sell
531,569
-23,376
-4% -$4.85M 0.02% 547
2020
Q2
$96.8M Buy
554,945
+16,106
+3% +$2.57M 0.02% 584
2020
Q1
$68M Buy
538,839
+17,751
+3% +$2.66M 0.02% 626
2019
Q4
$79.6M Buy
521,088
+21,920
+4% +$3.03M 0.02% 702
2019
Q3
$66.1M Buy
499,168
+8,348
+2% +$1.12M 0.02% 747
2019
Q2
$69.6M Buy
490,820
+14,176
+3% +$1.92M 0.02% 716
2019
Q1
$69.2M Buy
476,644
+19,115
+4% +$2.51M 0.02% 687
2018
Q4
$51.8M Buy
457,529
+28,878
+7% +$3.62M 0.02% 714
2018
Q3
$57.7M Buy
428,651
+5,024
+1% +$620K 0.02% 738
2018
Q2
$47.6M Sell
423,627
-9,603
-2% -$1.04M 0.01% 786
2018
Q1
$46.2M Buy
433,230
+617
+0.1% +$66.5K 0.02% 771
2017
Q4
$47.3M Buy
432,613
+28,456
+7% +$3.1M 0.02% 726
2017
Q3
$43.7M Buy
404,157
+28,908
+8% +$2.97M 0.02% 749
2017
Q2
$38M Buy
375,249
+5,377
+1% +$495K 0.01% 787
2017
Q1
$33.3M Buy
369,872
+30,490
+9% +$2.59M 0.01% 834
2016
Q4
$25.9M Buy
339,382
+13,499
+4% +$1.03M 0.01% 913
2016
Q3
$27.2M Buy
325,883
+13,597
+4% +$1.14M 0.01% 811
2016
Q2
$25.7M Buy
312,286
+9,346
+3% +$770K 0.01% 795
2016
Q1
$23K Buy
302,940
+32,224
+12% +$2.39M 0.01% 845
2015
Q4
$21.8M Sell
270,716
-686
-0.3% -$49.5K 0.01% 842
2015
Q3
$17.2M Buy
271,402
+12,746
+5% +$915K 0.01% 966
2015
Q2
$18.2M Sell
258,656
-1,204
-0.5% -$89.1K 0.01% 988
2015
Q1
$20.6M Buy
259,860
+14,070
+6% +$1.04M 0.01% 905
2014
Q4
$15.6M Sell
245,790
-11,313
-4% -$709K 0.01% 1023
2014
Q3
$15.4M Sell
257,103
-413
-0.2% -$23.6K 0.01% 983
2014
Q2
$13.8M Buy
257,516
+20,274
+9% +$1.11M 0.01% 1068
2014
Q1
$14.3M Buy
237,242
+19,029
+9% +$1.11M 0.01% 1009
2013
Q4
$11.6M Buy
218,213
+21,527
+11% +$1.08M 0.01% 1093
2013
Q3
$9.1M Buy
196,686
+9,379
+5% +$430K 0.01% 1137
2013
Q2
$7.68M Buy
+187,307
New +$8.03M 0.01% 1124

Other funds holding CRL

Geode Capital Management's CRL Position: Q2 2026 in Review

Geode Capital Management increased its Charles River Laboratories (CRL) stake by 0% in Q2 2026, buying an estimated $7.83K and bringing the position to 1,305,738 shares worth $296M. The position accounts for 0.02% of the portfolio, ranked #644.

Geode Capital Management first reported a position in CRL in Q2 2013 and has held it in 53 quarters since. The position peaked at $375M in Q3 2021. 521 funds tracked by Wall St. Rank hold CRL as of Q2 2026.

  • Geode Capital Management held 1,305,738 shares of Charles River Laboratories worth $296M as of Q2 2026.
  • Geode Capital Management bought 44 Charles River Laboratories shares in Q2 2026, an estimated $7.83K.
  • Charles River Laboratories made up 0.02% of Geode Capital Management's portfolio in Q2 2026, its #644 holding.
  • Geode Capital Management first reported a position in Charles River Laboratories in Q2 2013 and has held it in 53 quarters since.
  • Geode Capital Management's Charles River Laboratories position peaked at $375M in Q3 2021.
  • 521 funds tracked by Wall St. Rank held Charles River Laboratories as of Q2 2026.

Based on Geode Capital Management's 13F filing for Q2 2026, filed 12 Aug 2026.